Acrivon Initial Positive Data for ACR-368, Pipeline Progress
24 Apr 2024 //
PRESS RELEASE
Acrivon R&D Event Highlights ACR-368, ACR-2316, AP3 Platform
16 Apr 2024 //
PRESS RELEASE
Acrivon AACR Data on AP3 for ACR-2316, ACR-368 Resistance
10 Apr 2024 //
PRESS RELEASE
Acrivon Therapeutics Announces $130 Million Private Placement Financing
09 Apr 2024 //
PRESS RELAESE
A startup plans an IPO to give a shelved Lilly drug another shot
19 Oct 2022 //
BIOPHARMADIVE
Akoya Bio Partners with Acrivon Tx for Acrivon`s Proprietary OncoSignature Test
28 Jun 2022 //
GLOBENEWSWIRE
Acrivon snags $100M to bring Lilly cancer drug into 19th study
12 Nov 2021 //
FIERCEBIOTECH